Not independent
Tenure on this board
4.6 yrs
Also a director at
Enlivex Ltd (ENLV)
Meeting calendar
INDP · Special meeting · Friday, July 25, 2025
Indaptus Therapeutics Inc
10 nominees · 2 ballot items.
Stockholders are asked to approve two management proposals: Issuance of shares underlying notes and common warrants issued in a private placement under Nasdaq Listing Rule 5635(d), and issuance of shares underlying notes and warrants to the Related Party (CEO/director Jeffrey Meckler) under Nasdaq Listing Rule 5635(c).
Market cap
$333M
1Y TSR
-68.6%
Board grade
C-
Record date
Jun 16, 2025
Filing
DEF 14A
Meeting concluded · Jul 25, 2025
Follow how the vote landed and what changed on Indaptus Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Issuance Proposal
ManagementBoard: FORStockholders are asked to approve the issuance of shares of common stock underlying notes and warrants issued or issuable in the ongoing private placement, including common warrants, pre-funded warrants, and placement agent warrants, in order to comply with Nasdaq Listing Rule 5635(d).
- 2
Related Party Proposal
ManagementBoard: FORStockholders are asked to approve the issuance of shares underlying notes and warrants to the Related Party (CEO and Director Mr. Jeffrey Meckler) under Nasdaq Listing Rule 5635(c), in connection with the private placement, to permit conversion/exercise as specified.
Director elections
Nominees on the ballot10
Not independent
Tenure on this board
4.5 yrs
Not independent
Tenure on this board
4.6 yrs
Also a director at
Travere Therapeutics Inc (TVTX)
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
4.4 yrs
Also a director at
Dariohealth Corp (DRIO)
Independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
4.6 yrs
Also a director at
Builders Firstsource Inc (BLDR)
Independent
Tenure on this board
4.2 yrs
Independent
Tenure on this board
2.9 yrs
Ownership
Latest 13F quarterTop institutional holders7
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 0.0% | 39,018 | $71K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 0.0% | 26,292 | $48K |
| 3 | MORGAN STANLEY | 0.0% | 2,697 | $5K |
| 4 | Tower Research Capital LLC (TRC | 0.0% | 1,890 | $3K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.0% | 715 | $1K |
| 6 | SBI Securities Co., Ltd. | 0.0% | 17 | $31 |
| 7 | CWM, LLC | 0.0% | 2 | $4 |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Indaptus Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Seer IncSEER
Annual meeting·Jul 28, 2026·$91M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Reference
Frequently asked questions
- When is the Indaptus Therapeutics Inc 2025 special meeting?
- Indaptus Therapeutics Inc (INDP) holds its 2025 special shareholder meeting on Friday, July 25, 2025.
- What is the record date for the Indaptus Therapeutics Inc 2025 meeting?
- The record date for the Indaptus Therapeutics Inc 2025 meeting is Monday, June 16, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Indaptus Therapeutics Inc's 2025 meeting?
- The board is presenting 10 director nominees at the Indaptus Therapeutics Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Indaptus Therapeutics Inc 2025 meeting?
- Shareholders will vote on 2 proposals at the Indaptus Therapeutics Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.